Researchers are developing vaccine against recurrent breast cancer
Patients who need a prescription to buy Canadian Tamoxifen need to be cautious of recurrent breast cancer once their treatment ends.
Patients who need a prescription to buy Canadian Tamoxifen need to be cautious of recurrent breast cancer once their treatment ends. Currently, researchers from Brooke Army Medical Center in Houston are developing a vaccine that may help prevent this type of malignancy.
The recently completed Phase II trial included 217 women who were treated for breast cancer and considered disease-free at the start of the study. The scientists administered the HER2-based peptide vaccine AE37 to 109 women, while treating the rest of the subjects as controls.
"The theory is that once you form that response to the specific peptide, if the body has a recurrence, it will recognize that cancer as a bad thing, a foreign thing," said researcher Diane Hale, MD.
Some time later, the scientists injected all the women with a non-therapeutic dose of the vaccine. Those who received the peptide earlier showed a much stronger immune reaction.
Furthermore, the researchers discovered that analyzing the immune responses of these women could help them predict who is likely to experience recurrent disease.
The results were presented at the American Association for Cancer Research Annual Meeting 2012.
|
my account
